Colposeptine + Metronidazole
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Vaginosis, Bacterial
Conditions
Vaginosis, Bacterial
Trial Timeline
Jul 1, 2010 → Nov 1, 2010
NCT ID
NCT01153958About Colposeptine + Metronidazole
Colposeptine + Metronidazole is a approved stage product being developed by Merck for Vaginosis, Bacterial. The current trial status is terminated. This product is registered under clinical trial identifier NCT01153958. Target conditions include Vaginosis, Bacterial.
What happened to similar drugs?
3 of 4 similar drugs in Vaginosis, Bacterial were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01153958 | Approved | Terminated |
Competing Products
5 competing products in Vaginosis, Bacterial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 100 mg clindamycin /800 mg ketoconazole vaginal ovule + 100 mg tetracycline hydrochloride /50 mg amphotericin B cream | Merck | Phase 3 | 40 |
| Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring | Merck | Approved | 39 |
| metronidazole and azithromycin | Pfizer | Approved | 43 |
| Lactoserum (Dermacyd Femina®) | Sanofi | Approved | 43 |
| BNT331 | BioNTech | Phase 1 | 26 |